| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9808431 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
| US9549907 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
| US10105324 | SOVEREIGN PHARMS | Immediate release oral guaifenesin solution |
Nov, 2035
(11 years from now) | |
Obredon is owned by Sovereign Pharms.
Obredon contains Guaifenesin; Hydrocodone Bitartrate.
Obredon has a total of 3 drug patents out of which 0 drug patents have expired.
Obredon was authorised for market use on 14 November, 2014.
Obredon is available in solution;oral dosage forms.
Obredon can be used as a method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or increases the auc (0-inf) by at least 1.4.
The generics of Obredon are possible to be released after 13 November, 2035.
Drugs and Companies using GUAIFENESIN; HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 14 November, 2014
Treatment: A method of increasing the bioavailability of guaifenesin in a solution containing 54% to 66% by weight of propylene glycol and glycerol, wherein the method increases the cmax by at least 1.5 and/or i...
Dosage: SOLUTION;ORAL
OBREDON family patents
